Treatment with Propiverine in Children Suffering from Nonneurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase 3 Clinical Trial

Marschall-Kehrel, Daniela; Feustel, Cornelia; Geeter, Charlotta Persson de; Stehr, Maximilian; Radmayr, Christian; Sillén, Ulla; Strugala, Gerhard

doi:10.1016/j.eururo.2008.04.062

Cited by 67 publications

(49 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 Aside from oxybutynin, which is FDA-approved for children, reports on use in children with OAB are provided for tolterodine, trospium and propiverine. [5][6][7][8][9][10][11][12] Hoebeke and colleagues performed a retrospective uncontrolled study in 138 children with therapy resistant non-neurogenic overactive bladder whom they treated with solifenacin for a mean of 23 months. They found solifenacin effective with an overall 85% response rate, a full response in more than 50% and side effects in only 6.5% of their cohort.…”

Section: Discussionmentioning

confidence: 99%

“…4 Data about the safety and efficacy of newer agents in children are scarce. Although there have been reports about the use of tolterodine, 5-9 trospium 10 and propiverine 11,12 in children, to date only oxybutynin chloride has been officially approved for pediatric use by medical authorities in North America. Solifenacin is a tertiary amine approved by the FDA for OAB in adults since 2005.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study

Nadeau

Schröeder

Moore

et al. 2014

CUAJ

View full text Add to dashboard Cite

Introduction: We evaluate the efficacy and safety of solifenacin to treat incontinence in children with non-neurogenic (DO) or neurogenic detrusor overactivity (NDO) refractory to oxybutinin or tolterodine. Methods: We updated and extended our previously published nonrandomized uncontrolled study on open-label use of adjusted-dose regimens of solifenacin (1.25-10 mg) in children with refractory incontinence. The follow-up included voiding diaries, post-void residuals, urine cultures, ultrasounds and urodynamic studies. Clinical data were updated as of September 2012. Subjective improvement was assessed with the Patient Perception of Bladder Condition (PPBC) scale. The primary end point was efficacy toward continence and secondary end points were tolerability and safety. Results: Overall, 244 patients (112 girls, 132 boys) were enrolled; 53 with NDO and 191 with DO. Minimal follow-up was 5 months, the mean duration of treatment was 21.0 months and the mean age at initiation was 9.2 years. Urodynamic capacity improved from 145 ± 76 mL to 339 ± 152 mL and the amplitude of uninhibited contractions decreased from 66 ± 26 to 20 ± 20 cmH 2 O (p < 0.0001). The overall success rate is 91%, and more specifically 94% for non-neurogenic and 79% for neurogenic, which is significantly different (p = 0.013). Twenty-three patients discontinued treatment for unsatisfactory clinical response or bothersome side effects. No side effects were reported by 175 patients, mild by 46, moderate by 9, and 14 withdrew due to their side effects. Ten patients developed post-void residuals of ≥20 mL. Conclusion: Although higher in the non-neurogenic group, high subjective and objective success rates were maintained over a longer follow-up with an adjusted-dose regimen of solifenacin to treat pediatric NDO or DO refractory to oxybutynin or tolterodine. Moreover, we found acceptable tolerability and safety profiles.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study

Nadeau

Schröeder

Moore

et al. 2014

CUAJ

View full text Add to dashboard Cite

show abstract

“…Its efficacy in children has been assessed in a multicentre, placebo-controlled, double-blind study that demonstrated significant improvement in urinary frequency, incontinence episodes and mean voided volume. 40 Kim et al reported an overall response rate of 86.8% in a retrospective review of 68 children. 41 A multicentre, observational, cohort study comparing propiverin to oxybutynin demonstrated that propiverine was at least as effective as oxybutynin and that it had a favourable tolerability profile over oxybutynin.…”

Section: Other Antimuscarinic Agentsmentioning

confidence: 99%

Overactive bladder in children

Ramsay¹,

Bolduc²

2017

CUAJ

View full text Add to dashboard Cite

Overactive bladder (OAB) is a highly prevalent disorder in the pediatric population. This condition is especially troublesome for pediatric patients and their families when associated with incontinence, since it negatively affects self-esteem and impairs children's development. From the patient's perspective, urgency and urge incontinence can have a significant impact, negatively affecting their quality of life. For a therapy to have true benefit, changes must not only be statistically significant, but must also be perceived as meaningful by the patient. A stepwise approach is favoured to treat this pathology, starting with behavioural therapy, followed by medical management, and eventually more invasive procedures.Antimuscarinic agents are the mainstay of medical treatment for OAB. Oxybutynin is the most commonly used antimuscarinic in the pediatric population. However, some patients have a suboptimal response to antimuscarinics and many experience bothersome side effects, which have been documented with all antimuscarinics to a significantly higher degree than placebo. Although there have been reports about the use of tolterodine, fesoterodine, trospium, propiverine, and solifenacin in children, to date, only oxybutynin has been officially approved for pediatric use by medical authorities in North America. This review will address alternative treatment options for pediatric patients presenting with OAB, from conservative measures to more invasive therapies.

show abstract

“…Aşırı aktif mesane ya da idyopatik detrusor aşırı aktivitesi tanısı alan çocuk ve ergen hastaları kapsayan randomoze, çift kör, çok merkezli, 2 retrospektif ça-lışmada propiverinin etkinliği değerlendirilmiştir. Bu çalışmanın sonucunda günlük işeme sayısında, inkontinans atağı sayısında anlamlı azalmalar saptanırken işenen idrar hacminde ortalama 31,4 mL'lik bir artış saptanmıştır (26). Nörojenik detrusor aşırı aktivitesi tanısı alan çocuk ve ergen hastaları kapsayan çalışma-da ise propiverin tedavisi sonucu maksimum detrusor basıncın-da 19 cm H 2 O'luk bir azalma saptanırken maksimum sistometrik kapasitede ve mesane kompliyansında anlamı artışlar tespit edilmiştir (27).…”

Section: Karma Etki Ile Elde Edilen Klinik Sonuçlarunclassified

Asiri Aktif Mesane Tedavisinde Karma Etkili Ajanların Etki Mekanizmasi ve Avantajlari

Karakeçi¹,

Onur²

2016

Kontinans ve Nöroüroloji Bülteni

View full text Add to dashboard Cite

Treatment with Propiverine in Children Suffering from Nonneurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase 3 Clinical Trial

Cited by 67 publications

References 15 publications

Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study

Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study

Overactive bladder in children

Asiri Aktif Mesane Tedavisinde Karma Etkili Ajanların Etki Mekanizmasi ve Avantajlari

Contact Info

Product

Resources

About